News & Updates
Filter by Specialty:
Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis
A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.
Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis
19 Oct 2023
ARCADIA trials: A win for nemolizumab in atopic dermatitis
In the phase III ARCADIA 1 and 2 trials, the investigational, first-in-class interleukin-31-Rα antagonist nemolizumab delivered early, rapid, and sustained improvements in the core signs and symptoms of atopic dermatitis (AD) in patients with moderate-to-severe disease.
ARCADIA trials: A win for nemolizumab in atopic dermatitis
17 Oct 2023
ALA-PDT on par with minocycline for moderate-to-severe rosacea
Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.
ALA-PDT on par with minocycline for moderate-to-severe rosacea
08 Oct 2023
Too much animal-based protein poses increased AD risk
Frequent intake of high-protein foods in diets, especially those derived from animals, appears to be associated with an increased risk of atopic dermatitis (AD) and allergic sensitization to common house dust mites, according to a study.
Too much animal-based protein poses increased AD risk
28 Sep 2023
Does UV-B phototherapy increase the risk of skin cancer in AD patients?
Ultraviolet (UV)-B phototherapy does not appear to increase the risk of skin cancer in patients with atopic dermatitis (AD), reveals a study.